Temperature‐Controlled Radiofrequency for Severe Nasal Airway Obstruction: A Non‐Inferiority Comparison With Surgical Intervention Authors: Greg Davis, Zeeshan Aziz, Jose Barrera, William Blythe, Chris Davis, Steven Davis, Thomas Higgins, Charles Lano, Gregory Levitin, Frederick Lopatin, Samuel Oyer, Stacey Silvers, Ariel Waitzman, Randall Ow Published: 2026 ABSTRACT ABSTRACTIntroductionTemperature‐controlled radiofrequency (TCRF), septoplasty (ST) with turbinate reduction, and functional rhinoplasty (FR) are treatment options for nasal airway obstruction (NAO) and nasal valve dysfunction (NVD), but no direct comparison of these procedures has been performed.MethodsThis prospective, open‐label, non‐inferiority (NI) trial, conducted at 29 US sites, used a prespecified NI margin and inverse probability of treatment weighting to simulate randomization and facilitate an unbiased comparison of TCRF to ST and FR in adults with Nasal Obstruction Symptom Evaluation scores ≥ 55 and NVD. NI was determined using a 15% difference in the 3‐month responder rate (≥ 24‐point NOSE score improvement) for TCRF compared to ST and FR. Additional analyses included return to work/regular activities (RTW) and adverse events (AEs).ResultsA total of 174 patients were treated (116 TCRF and 58 surgery [35 ST, 23 FR]). At 3 months, TCRF was non‐inferior to surgery with a 90.5% responder rate compared to 94.3% for ST (mean difference: 0.04 [95% CI, −0.02 to 0.11]; p < 0.001) and 95.7% for FR (mean difference: −0.12 [95% CI, −0.23 to 0]; p < 0.001). TCRF median RTW was 1 day versus 5.5 and 7.5 days for ST and FR, respectively. TCRF had fewer AEs than surgery (6.9% TCRF patients vs. 19.0% for surgical arms combined).ConclusionsTCRF patient treatment response was non‐inferior to ST and FR, with fewer AEs and faster RTW. These findings support TCRF as a minimally invasive alternative to nasal surgery for patients with NAO and NVD.Trial RegistrationClinicalTrials.gov identifier: NCT06922955 Introduction Nasal valve dysfunction (NVD), including static and dynamic collapse, a common cause of nasal airway obstruction (NAO), impairs nasal airflow, interferes with breathing, and negatively impacts quality of life [1, 2]. NAO is often attributed to more than one anatomic cause. Interventions that create space in the nasal airway, whether by reducing a septal deviation (SD), stabilizing the nasal valve, or both, can substantially improve nasal airflow. Because nasal valve collapse reflects an underlying anatomic deficiency, medical therapy alone is often inadequate to restore durable airway patency, and surgical interventions, such as septoplasty (ST) with turbinate reduction and functional rhinoplasty (FR) procedures (with or without ST with turbinate reduction) are traditionally performed to address structural contributors to NAO [3]. The recent availability of temperature‐controlled radiofrequency (TCRF) technology as a treatment option for NAO and NVD expands the therapeutic landscape, introducing an important option for physicians and patients. The emerging role of TCRF as a minimally invasive alternative to traditional surgical approaches is important to consider in the context of structural NAO management, including decision‐making, placement in care pathways, medical policy, and coverage decisions [3]. FR, widely regarded as the gold standard for effectively treating NVD, stabilizes the lateral nasal wall to restore nasal patency [4, 5], and often involves tissue harvesting, implantation of grafts, and cartilage manipulation. However, it can be associated with adverse events (AEs) such as hypertrophic scarring (up to 1.5%), infection (up to 4%), septal perforation (up to 2.6%), dehiscence (up to 5%), graft resorption or displacement, and prolonged edema [6, 7, 8]. Although uncommon, some complications can lead to revision surgery in up to 11% of cases [7, 9]. ST, often combined with turbinate reduction, is commonly performed to address SD‐related NAO and may provide adequate relief of NAO for some patients when NVD is not the main contributor. Some patients may have persistent NAO symptoms because underdiagnosed NVD may require subsequent NV surgery [10]. ST is associated with bleeding and infection rates of up to 4% [11] and occasionally results in septal perforation, sensory changes, and cosmetic deformities [12]. While revision rates are relatively low [13], up to a third of ST patients experience persistent nasal obstruction symptoms [14, 15], with more than 80% of these patients having undiagnosed NVD [16]. Although both FR and ST procedures are well established and effective, these procedures are invasive, require general anesthesia, and must be performed in an operating room. Surgical recovery often requires postoperative restrictions and pain management, contributing to lost workdays, incurring higher direct costs for postoperative care and higher indirect costs related to productivity losses [17]. These factors can discourage patients from seeking interventions for NAO, which frequently coexists with other comorbid conditions such as asthma, obesity, and gastroesophageal reflux disease, compounding symptom severity and treatment complexity [18]. TCRF is an effective, durable, and minimally invasive procedure for the repair of NAO and NVD that may be performed with local anesthesia in an office setting [19, 20, 21, 22]. TCRF uses radiofrequency energy to remodel nasal valve cartilage and reduce soft tissue hypertrophy of the inferior turbinates and septal swell bodies, promoting collagen contraction and tissue remodeling while preserving mucosal integrity. TCRF treatment of NAO has demonstrated durable symptom reductions for up to 4 years [22, 23, 24]. Complications from TCRF include mild to moderate epistaxis (up to 1.9%), infection (up to 1.6%), transient nasal soreness (0.8%), and congestion (2.8%), which generally resolve with healing [21, 22, 23, 24], and revision rates are < 3% [25]. TCRF treatment of NAO has been shown to provide significant reductions in posttreatment health‐resource utilization, including reductions in subsequent surgeries, nasal medication use, and office visits, as well as substantial cost savings compared to medically managed controls [25]. In a recent meta‐analysis, Han et al. compared outcomes for TCRF and FR, which showed that patients undergoing TCRF or FR treatment of nasal valve collapse had similar NAO symptom reductions at 3 months, with both approaches showing incremental gains at 12 months [26]. To date, no studies have been performed directly comparing TCRF with standard surgical procedures for NAO. Randomized controlled trials (RCTs), considered the gold standard for treatment comparisons, are particularly challenging and often practically infeasible to conduct when comparing minimally invasive technology to more invasive surgical interventions. Differences in procedural risks, treatment settings, perioperative recovery, and patient and physician treatment preferences limit the feasibility of random treatment assignment. As an alternative to an RCT, a non‐inferiority (NI) trial design can enable direct comparisons of distinctly different procedures to evaluate whether the new treatment is inferior to established treatment using a clinically meaningful equivalence margin [27]. Incorporating inverse propensity weighting (IPTW) enables simulation of randomization while removing selection bias to enable observation of an average treatment effect for each intervention. Here, we report preliminary findings directly comparing TCRF to ST and FR for the treatment of patients with severe/extreme NAO and NVD using a NI trial design. Materials and Methods Study Design and Procedural Interventions This study was a prospective, open‐label, three‐arm, multicenter, NI trial evaluating TCRF outcomes compared to ST and FR. Patients were enrolled at 29 otolaryngology clinics across the United States with treatment performed by board‐certified otolaryngologists. Sites were assigned to one specific treatment arm (ST, FR, or TCRF) based on the investigator's usual care pathway for the treatment of NAO with NVD. Patients were surgical candidates with scheduled ST and FR procedures, and those in the TCRF arm received the office‑based procedure as an alternative to surgical SD or NV repair. To approximate randomization and address potential baseline imbalances, IPTW, using a covariate balancing propensity score, was applied across all analyses to enable comparisons between treatment groups. Institutional review board approval was obtained at all sites, with patients providing informed consent before enrollment. Patients in the TCRF arm had treatment of the lateral nasal wall in the area of the upper lateral cartilage using the VivAer device (Aerin Medical, Mountain View, CA, USA) in an office setting under local anesthesia according to the manufacturer's instructions for use. In addition, TCRF treatment of the inferior turbinate and/or septal swell body was allowed per investigator's discretion according to individual patient needs. ST and FR procedures were performed under general anesthesia in an operative setting. FR procedures focused on nasal valve repair with adjunctive ST performed at the physician's discretion. This prespecified interim analysis was conducted 3 months post‑procedure to assess treatment effectiveness and safety. Inclusion and Exclusion Criteria Key inclusion criteria included patients aged 22–85 years seeking treatment for NAO with baseline Nasal Outcome Symptom Evaluation (NOSE) Scale score ≥ 55, and a positive modified Cottle maneuver. Key exclusion included previous rhinoplasty (functional or cosmetic), ST, inferior turbinate reduction, TCRF procedure; severe nasal pathology or trauma; abnormal nasal conditions (e.g., septal perforation or empty nose syndrome) that may be exacerbated by surgery, and planned sinonasal or cosmetic nasal surgery or surgery involving the airway (e.g., hypoglossal nerve stimulation surgery) within 6 months following enrollment. Combined adjunctive procedures extending beyond the defined interventions, including primary cosmetic rhinoplasty, were not permitted. See Table S1 for all study entry criteria. Endpoints The comparison of responder rates for the treatment (ST and FR) 3 months post‐procedure (defined as a ≥ 24‐point decrease in the validated NOSE score) was based on a published minimum clinically important difference standard [28]. The NOSE score uses a 5‐point Likert scale to calculate a total score ranging from 0 to 100. The NI of TCRF to the surgical arms was evaluated using the difference in proportions of responders between the two arms using a prespecified NI margin of 15%, based on clinical judgment relative to expected outcomes from standard surgical care, also consistent with margins commonly used in procedural NI trials [29, 30]. Additional endpoints included evaluation of the NI of TCRF responder rates to surgical arms individually at 3 months post‐procedure. Additional comparisons included changes from baseline in NOSE scores, distribution of NOSE score severity categories (mild [5–25], moderate [30–50], severe [55–75], or extreme [80–100]), and post‐procedure recovery (including return to work (RTW)/normal activities) via patient questionnaires. Safety assessments, including incidence and type of procedure‐ and device‐related AEs, were reported at each study visit through 3 months post‐procedure. Sample Size and Statistical Analysis To achieve 90% power, a one‐sided α = 0.025 was used. A minimum sample size for this prespecified interim analysis required 167 patients to demonstrate NI with 2:1 allocation of TCRF to the surgical interventions. A weighted generalized linear model was used to estimate treatment effect differences between groups using a binary response outcome. IPTWs were derived using a covariate balancing propensity score model. Propensity weights were derived using a model incorporating the following baseline covariates: age, sex, NOSE scores, SD, and investigative site type. Covariate balance after weighting was confirmed using a standardized mean difference (SMD) < 0.1, indicating equivalence between treatment arms. Unweighted analysis was performed to verify that the observed treatment effects were consistent in direction and magnitude without model adjustment. Post hoc subgroup analyses were conducted to evaluate treatment effectiveness by baseline SD severity across treatment arms. Subjects were stratified into severe and extreme SD categories, and changes from baseline in the NOSE score and responder rates at 3 months were compared descriptively across treatment groups. Continuous variables were summarized using the mean, least‐squares (LS) means, standard deviations, and median (range). Categorical data were summarized by frequency and percentage; 95% confidence intervals (CIs) were reported for mean or proportion differences. Student's t tests and Fisher's exact tests were used to compare secondary endpoints. Statistical significance was defined as p < 0.05. All analyses were performed on the per‐protocol population (e.g., met all eligibility criteria, had 3‐month outcomes, and had no exclusionary protocol deviations) using R (version 4.5) and corresponding packages. Results Subject Disposition and Baseline Characteristics A total of 193 patients were enrolled (126 TCRF, 43 ST, and 28 FR). See Figure 1 for patient disposition. At baseline, the three treatment arms were generally comparable (Table 1). However, patients in the TCRF arm were slightly older with a mean age of 55 (±17) years compared to 45 (±16) years in the ST arm and 44 (±13) years in the FR arm (p < 0.001 for both vs. TCRF). Before weighting, patients in the surgical groups were younger and had higher proportions of severe SD and extreme baseline NAO symptoms. After IPTW application, these baseline differences were minimized, achieving statistical balance across groups (SMD < 0.1 for all covariates). Nasal characteristics (e.g., inferior turbinate hypertrophy, nasal polyps) were similar, with chronic rhinitis (allergic, nonallergic, or mixed) documented in 35.3% of patients in the TCRF arm compared with 20.0% and 26.1% in the ST and FR arms, respectively. Patients in the ST and FR arms had a higher proportion of severe SDs. All FR patients had concomitant ST, and TCRF patients had a combination of isolated nasal valve treatment with and without soft tissue treatment (see Table S2). Consort flowchart of subject disposition and analysis populations. CONSORT, Consolidated Standards of Reporting Trials; FU, follow‐up; Fx Rhino, functional rhinoplasty; ITT, intent‐to‐treat; LTF, lost to follow‐up; PD, protocol deviation; PP, per protocol; SF, screen failure; W/D, withdrawn. TABLE 1Demographics and baseline nasal characteristics.TCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23AgeMean (SD)55.2 (17.1)44.9 (15.8)43.6 (13.1)Age category22–59 years57 (49.1)27 (77.1)19 (82.6)≥60 years59 (50.9)8 (22.9)4 (17.4)SexFemale47 (40.5)11 (31.4)12 (52.2)Male69 (59.5)24 (68.6)11 (47.8)RaceWhite107 (92.2)33 (94.3)20 (87.0)Asian6 (5.2)2 (5.7)2 (8.7)Black or African American2 (1.7)00Mixed1 (0.9)00Missing001 (4.3)EthnicityHispanic or Latino8 (6.9)2 (5.7)8 (34.8)Not Hispanic or Latino108 (93.1)33 (94.3)15 (65.2)Nasal polypsNo13 (11.2)1 (2.9)3 (13.0)Unknown103 (88.8)34 (97.1)20 (87.0)Septal swell body hypertrophyPresent106 (91.4)8 (22.9)14 (60.9)Not present10 (8.6)27 (77.1)9 (39.1)Septal deviationPresent91 (78.4)35 (100)23 (100)Not present25 (21.6)00Septal deviation severity a None25 (21.6)00Mild43 (37.1)00Moderate28 (24.1)7 (20)9 (39.1)Severe17 (14.7)23 (65.7)9 (39.1)Extreme3 (2.6)5 (14.3)5 (21.7)Inferior turbinate hypertrophyPresent115 (99.1)35 (100)22 (95.7)Not present1 (0.9)01 (4.3)Chronic rhinitisAllergic26 (22.4)6 (17.1)4 (17.4)Nonallergic2 (1.7)00Mixed allergic/nonallergic13 (11.2)1 (2.9)2 (8.7)Unknown75 (64.7)28 (80)17 (73.9)Baseline NOSE (SD)75.2 (15.3)80.4 (12.2)77.5 (12.7)Abbreviations: N, number of subjects; SD, standard deviation. a Septal deviation severity was defined as: mild = occupies ≤ 25% of the nasal passage, moderate = occupies > 25%–≤ 50% of the nasal passage, severe = occupies > 50%–≤ 75% of the nasal passage, and extreme = occupies > 75% of the nasal passage.John Wiley & Sons, Ltd. Demographics and baseline nasal characteristics. Abbreviations: N, number of subjects; SD, standard deviation. Septal deviation severity was defined as: mild = occupies ≤ 25% of the nasal passage, moderate = occupies > 25%–≤ 50% of the nasal passage, severe = occupies > 50%–≤ 75% of the nasal passage, and extreme = occupies > 75% of the nasal passage. Endpoints At 3 months, 90.5% of TCRF patients (105/116) were responders compared to 94.3% for the ST and 95.7% for FR arms. Non‐inferiority of TCRF to each surgical comparator was demonstrated for the comparison to each surgical arm separately, with weighted differences in responder rates of 0.04 (95% CI, −0.02 to 0.11; p < 0.001) for ST and −0.12 (95% CI, −0.23 to 0.0; p < 0.001) for FR. Figure 2 shows weighted differences in responder rates and NI margins for each treatment arm compared with TCRF. The proportion of participants achieving a ≥ 24‑point improvement from baseline in NOSE score at 3 months. Analyses compared TCRF with the surgical groups together, septoplasty, and functional rhinoplasty individually. Non‐inferiority was achieved for all comparisons (p < 0.001 vs. each comparator). The results of the unweighted analysis for responder rates by arm were consistent in both direction and magnitude with the weighted results (Table 2). The difference in responder rates between TCRF and surgical arms was −3.8 (95% CI, −13.1 to 5.6; p = 0.009) between TCRF and ST and −5.1 (95% CI, −15.0 to 4.8; p = 0.025) for FR. Across all comparisons, the unadjusted results remained within the prespecified NI margin, demonstrating NI of TCRF to each surgical arm. The consistency between weighted and unweighted analyses confirms that observed differences were not driven by baseline imbalances. TABLE 2Non‐inferiority of NOSE responder rate using IPTW and unweighted analysis.TCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23Surgery (ST + FR), N = 583 monthsResponder rate a , n (%)105 (90.5)33 (94.3)22 (95.7)55 (94.8)95% CI83.67, 95.1780.84, 99.378.05, 99.8985.62, 98.92Test of non‐inferiority vs. TCRF, IPTW b Weighted difference—0.04−0.12−0.0395% CI of difference—−0.02, 0.11−0.23, 0−0.11, 0.04 p value—<0.001<0.001<0.001Test of non‐inferiority vs. TCRF, unweighted c Difference—−3.8−5.1−4.395% CI of difference—−13.1, 5.6−15, 4.8−12.1, 3.5 p value—0.0090.0250.004Abbreviations: FR, functional rhinoplasty; N, number of subjects; n, number of observations; SD, standard deviation; ST, septoplasty. a Responder rate defined as ≥ 24‐point difference from baseline. b Covariate Balancing Propensity Score weighting model was used to test the proportion of responders with prespecified non‐inferiority margin of 15%. P values are from a score test on the difference of responder rates between surgical groups and TCRF that are estimated from a weighted logistic regression model. c Unweighted, observed analysis was used to test the proportion of responders with prespecified non‐inferiority margin of 15%. P values are from a one sample proportion test.John Wiley & Sons, Ltd. Non‐inferiority of NOSE responder rate using IPTW and unweighted analysis. Abbreviations: FR, functional rhinoplasty; N, number of subjects; n, number of observations; SD, standard deviation; ST, septoplasty. Responder rate defined as ≥ 24‐point difference from baseline. Covariate Balancing Propensity Score weighting model was used to test the proportion of responders with prespecified non‐inferiority margin of 15%. P values are from a score test on the difference of responder rates between surgical groups and TCRF that are estimated from a weighted logistic regression model. Unweighted, observed analysis was used to test the proportion of responders with prespecified non‐inferiority margin of 15%. P values are from a one sample proportion test. Mean baseline NOSE scores significantly improved across all treatment arms at 3 months. The mean TCRF NOSE scores decreased from 74.2 at baseline to 25.3 at 3 months, a mean change of −50.2 (95% CI, −54.9 to −45.6; p < 0.001) and a reduction of 65.9%. The results for the ST and FR arms analyzed separately showed mean reductions from baseline NOSE scores of −58.7 (95% CI, −67.2 to −50.1; p < 0.001) for ST and −48.7 (95% CI, −59.1 to −38.3; p < 0.001) for FR (Figure 3). No significant differences were observed in mean NOSE score reductions from baseline when comparing TCRF to the FR arm. However, there was a significant (p = 0.038) difference between the TCRF and ST arms. Adjusted LS mean NOSE score at baseline and 3 months across all arms. *p < 0.05 versus baseline score. Bars represent 95% CI. BL, baseline; CI, confidence interval; NOSE, nasal obstruction symptom evaluation. At baseline, all patients had severe or extreme NAO symptoms, with a greater proportion of patients in the surgical arms classified as extreme compared with TCRF (53.4% vs. 36.2%), see Table S3. At 3 months post‐procedure, the distribution of NOSE score severity categories shifted toward symptom resolution: 13.8% of TCRF patients and 15.5% of the surgical patients reported no NAO symptoms, and 48.3% of TCRF and 55.2% of patients reported mild symptoms. Moderate NAO symptoms persisted in 28.4% of TCRF patients and 20.7% of the surgical arm, with no significant differences in severity distribution between the surgical arms and TCRF (p = 0.358). Less than 10% of patients in any arm had severe to extreme NAO symptoms at 3 months (Figure 4). Proportion of participants in each NOSE score severity category at baseline and 3 months. NOSE, nasal obstruction symptom evaluation; TCRF, temperature‐controlled radiofrequency. Differences in NOSE score reductions at 3 months by baseline SD severity were analyzed to evaluate whether TCRF efficacy varied with SD severity (Table 3). Mean improvements in NOSE scores for TCRF ranged from −46.0 points in patients without SD to −52.7 for mild, −41.8 for moderate, −57.6 for severe, and −56.7 for extreme SD severity. Mean improvements in NOSE scores were similar in ST and FR patients with severe SDs, with NOSE score reductions of −59.3 and −56.1 points, respectively. Overall, TCRF produced substantial and consistent symptomatic benefit across all degrees of SD, achieving improvements comparable to surgical repair. Among patients with severe/extreme SD, no significant difference in NOSE scores was found between arms at baseline or 3 months: all treatments produced similar mean NOSE score reductions from baseline at 3 months (−57.5 for TCRF vs. −61.4 for ST and −50.4 for FR), indicating comparable symptom relief across treatment modalities in patients with severe/extreme SD (Table 4). TABLE 3Change of NOSE score from baseline by septal deviation severity.Septal deviation severityTCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23 n Mean (SD) n Mean (SD) n Mean (SD)None (no SD present)25−46.0 (27.3)0000Mild—Septal deviation occupies ≤25% of the nasal passage43−52.7 (19.7)0000Moderate—Septal deviation occupies >25%–≤50% of the nasal passage28−41.8 (22.8)7−62.1 (20.2)9−45.0 (12.7)Severe—Septal deviation occupies > 50%–≤75% of the nasal passage17−57.6 (17.2)23−59.3 (24.5)9−56.1 (19.3)Extreme—Septal deviation occupies >75% of the nasal passage3−56.7 (12.6)5−71.0 (24.6)5−40.0 (20.6)John Wiley & Sons, Ltd. Change of NOSE score from baseline by septal deviation severity. TABLE 4Summary of NOSE scores at baseline and 3‐month follow‐up in subjects with severe and extreme septal deviation.StatisticsTCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23 n 202814Baseline NOSE (SD)75.2 (15.3)80.4 (12.2)77.5 (12.7) p value a 0.2240.643NOSE at 3‐month (SD)17.8 (16.9)18.9 (21.2)27.1 (26.3) p value a 0.8310.253Score change (SD)−57.5 (16.3)−61.4 (24.5)−50.4 (20.6) p valuea 0.5080.291Abbreviation: SD, standard deviation. a p values are from a Student's t‐test comparing to TCRF.John Wiley & Sons, Ltd. Summary of NOSE scores at baseline and 3‐month follow‐up in subjects with severe and extreme septal deviation. Abbreviation: SD, standard deviation. p values are from a Student's t‐test comparing to TCRF. In addition, responder rates at 3 months were high (>80%) across all treatment arms regardless of SD severity: responder rates in patients with severe SDs were 100% for TCRF compared to 91.3% for ST and 100% for FR (Table S4). Return to Work The median time to RTW was significantly shorter for TCRF (1 day, range: 0–14 days) compared with 5.5 days (range: 1–21 days) in the ST arm and 7.5 days (range: 0–30 days) in the FR arm (p < 0.001 for each comparison) (Table 5). Similarly, the median time to return to regular daily activities was significantly shorter for TCRF (2 days) versus 14 and 15 days after ST and FR, respectively (p < 0.001 for each comparison). TABLE 5Days until returning to work and returning to regular activities after procedures.TCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23Surgery (ST + FR), N = 58Days until returning to workMean (SD)1.77.010.48.3Median (min, max)1 (0, 14)5.5 (1, 21)7.5 (0, 30)6.5, (0, 30)Q1, Q30, 2.24, 7.85, 134.8, 10 p value a —<0.001<0.001<0.001Days until returning to regular activitiesMean (SD)3.514.121.517.0Median (min, max)2 (0, 14)14 (3, 40)15 (2, 90)14, (2, 90)Q1, Q31, 59, 17.514, 25.510, 21 p value a —<0.001<0.001<0.001Abbreviations: FR, Functional rhinoplasty; N, number of subjects; SD, standard deviation; ST, septoplasty; TCRF, temperature‐controlled radiofrequency. a p values are from a Student's t‐test compared to TCRF.John Wiley & Sons, Ltd. Days until returning to work and returning to regular activities after procedures. Abbreviations: FR, Functional rhinoplasty; N, number of subjects; SD, standard deviation; ST, septoplasty; TCRF, temperature‐controlled radiofrequency. p values are from a Student's t‐test compared to TCRF. Safety Outcomes The incidence of procedure‐related AEs was low for all arms (Table 6). A total of eight (6.9%) procedure‐related AEs were reported in the TCRF arm, including separate events of dry nose, inflammation, migraine, nasal tenderness, nasal vestibulitis with cellulitis of the nasal tip, and epistaxis. One patient in the ST arm experienced dizziness, vision changes, and uvular enlargement. In the FR arm, eight (34.8%) AEs included separate events of nasal congestion, oral pain from the uvula, pain from undissolved stitches, edema, and one graft dislocation requiring revision surgery, which was deemed serious. All other AEs were mild to moderate and resolved at 3 months. TABLE 6Summary of device or procedure‐related adverse events.AE termTCRF, N = 116Septoplasty, N = 35Functional rhinoplasty, N = 23Total number of AEs8 (6.9)3 (8.6)8 (34.8)Dry nose1 (0.9)0 (0)0 (0)Epistaxis3 (2.6)0 (0)0 (0)Nasal inflammation1 (0.9)0 (0)0 (0)Migraine1 (0.9)0 (0)0 (0)Rhinalgia1 (0.9)0 (0)0 (0)Nasal vestibulitis1 (0.9)0 (0)0 (0)Edema0 (0)0 (0)3 (13)Graft complication0 (0)0 (0)1 (4.3)Pain0 (0)0 (0)1 (4.3)Stent dislocationa 0 (0)0 (0)1 (4.3)Sinusitis0 (0)0 (0)1 (4.3)Dizziness0 (0)1 (2.6)0 (0)Vision changes0 (0)1 (2.6)0 (0)Enlarged uvula0 (0)1 (2.6)0 (0)Oral pain0 (0)0 (0)1 (4.3)Abbreviations: AE, adverse event; TCRF, temperature‐controlled radiofrequency. a Device‐related.John Wiley & Sons, Ltd. Summary of device or procedure‐related adverse events. Abbreviations: AE, adverse event; TCRF, temperature‐controlled radiofrequency. Device‐related. Discussion This study represents the first direct comparison of an office‐based, minimally invasive TCRF procedure with established surgical interventions for NAO in patients with NVD. The trial enrolled patients presenting to otolaryngology clinics for evaluation and management of severe to extreme NAO symptoms, with participating sites performing procedures reflective of real‐world usual care, encompassing both surgical and minimally invasive treatment approaches. SD repair was selected as a comparator because it is among the most commonly performed surgical interventions for NAO and is frequently considered a first‐line surgical option, with the potential to indirectly improve nasal valve patency by correcting deviations that encroach upon the nasal valve region. FR was included because it is widely regarded as the gold standard surgical approach for definitive correction of NVD. A NI trial design was chosen for this direct comparison due to practical challenges associated with randomizing patients to standard surgical versus minimally invasive treatment approaches. In keeping with standards for reporting comparative trials [31], when evaluating comparative benefits of a new therapy to an existing standard. The primary clinical question addressed here is whether the newer TCRF approach, compared to the standard surgical approach for the treatment of NAO and NVD, achieves clinically acceptable effectiveness while offering meaningful secondary advantages. By framing the comparison around a prespecified and clinically relevant equivalence measure rather than superiority, this NI trial aligns with real‐world decision‐making and choice for physicians and patients alike. At 3 months, TCRF was non‐inferior compared to ST and FR. The results of weighted and unweighted analyses confirmed that NI was robust and not driven by baseline differences. Clinically meaningful and statistically significant improvements in NOSE scores were shown in all treatment arms, with large reductions from baseline reflecting substantial symptom relief, regardless of treatment method. Although the mean NOSE score improvement was numerically greater in the ST arm than in the TCRF arm, no significant differences were observed between TCRF and the FR arm, and all comparisons remained within the prespecified NI margin. The symptom severity distributions shifted toward mild or no obstruction, with fewer than 10% of patients reporting severe symptoms at 3 months, for all treatments. TCRF produced consistent improvements across all levels of SD severity, achieving outcomes comparable to surgical repair even in patients with severe or extreme deviation. Together, these findings indicate that TCRF provides clinically meaningful improvement that is non‐inferior to established surgical approaches, supporting its role as an effective, minimally invasive alternative in the management of NAO. A recent cost analysis by Kennedy et al. demonstrated that TCRF treatment was associated with approximately 40% (∼$21,000) lower total costs over 2 years compared with continued medical management [25]. While ST and FR remain important surgical options for NAO, these findings, together with real‐world evidence of reduced total cost of care following TCRF, strongly support its inclusion within the standard‐of‐care pathway for NAO related to NVD. FR remains the surgical gold standard for NAO by addressing both major structural contributors, the nasal valve and SD, whereas ST alone corrects SD without directly treating valve insufficiency. In contrast, TCRF targets the nasal valve through tissue remodeling without septal intervention. Although baseline NAO severity was modestly less extreme in the TCRF group, posttreatment severity distributions shifted toward symptom resolution and were comparable across all treatment arms. In addition, when NOSE score reductions were analyzed by baseline SD severity, improvements with TCRF were substantial across all severities, closely mirroring surgical outcomes for the severe group (−59.3 for ST and −56.1 for FR vs. −57.6 for TCRF). These findings demonstrate that TCRF produced consistent symptomatic benefit across all degrees of deviation severity, achieving improvements comparable to surgical repair despite targeting only the nasal valve, findings that align with a report by Tang et al., showing that TCRF efficacy is maintained regardless of SD severity at 3 months and sustained through 24 months post‐procedure [32]. Importantly, SD severity was included as a prespecified covariate in the weighting model, ensuring that comparative outcomes were evaluated after adjustment for baseline anatomical differences. Post hoc subgroup analyses evaluating treatment effects by arm with subjects stratified by SD severity showed no statistically significant differences in NOSE scores at baseline and 3 months. The responder rates were high for all treatment groups regardless of SD severity. These findings highlight the importance of considering minimally invasive treatment options for patients with NVD and severe/extreme SD. The median time to RTW of 1 day for TCRF versus 1 week for surgery highlights a compelling quality‑of‑life and productivity advantage. TCRF had fewer AEs than surgery (6.9% vs. 19.0%), and, overall, AEs were infrequent, mild/moderate, and transient, with one FR patient requiring revision surgery. These data, taken together with avoidance of general anesthesia, suggest that TCRF achieves surgical‐level symptom relief while minimizing perioperative risk and recovery time. As health systems and health plans increasingly emphasize the importance of improving patient outcomes as well as cost efficiency, there is growing recognition that, for appropriately selected patients, transitioning procedures from the operating room to the office setting can provide substantial benefits, including reductions in costs, risks, and inconvenience. The clinical performance of TCRF demonstrated in this study is consistent with multiple previously published studies [2, 19, 33, 34, 35], and taken together with available real‐world evidence [25], strongly supports the generalizability of these findings. While TCRF will not replace surgical options, these findings should encourage clinicians and patients alike to consider TCRF as a first‑line interventional option for NAO and NVD. This study has several limitations to consider. Sites were restricted to enrolling patients undergoing a single procedure (TCRF, ST, or FR), and although the treatment reflected usual care, it limited evaluation of outcomes for adjunctive procedures, which may be required in some instances. For example, in the ST arm, patients had NVD, but it was not addressed surgically. There may be an added benefit, in the interest of creating space in the nasal airway, to perform SD repair with TCRF NVD treatment to improve overall outcomes. Although each investigative site performed one procedural modality to preserve procedural consistency, and site was included as a prespecified covariate in the IPTW analysis, it may not be possible to completely mitigate potential site‐related bias without a randomized study design. As an RCT study design was not practical, including site as a covariate in the IPTW model is a reasonable way to minimize site‐related procedural selection bias. Allowing investigators to perform multiple procedures could have introduced additional bias, as physicians may preferentially assign patients to procedures based on subjective expectations of treatment success. Restricting sites to their established procedural approach ensured consistent patient selection criteria and standardized procedural techniques within each arm. To mitigate this potential limitation, IPTW using covariate‑balancing propensity scores was applied. Specifically, investigational site was included as a prespecified covariate because each site represented a single treatment arm. After weighting, all SMDs were < 0.1, indicating effective mitigation of potential site‐level bias. This approach represented the most rigorous and practical alternative to an RCT when direct procedural randomization was not feasible. In addition, the follow‐up duration represents another important limitation. This interim report provides results through 3 months, which, while seemingly limited, represents the minimum amount of time needed to reliably assess patient‐reported outcomes for nasal function and is reliably predictive of future outcomes for all three procedures [36, 37]. A systematic review and meta‐analysis by Han et al. demonstrated that NOSE score improvements following both TCRF and FR were comparable at 3 months with modest gains through 6‐ and 12‐month follow‐up, supporting the predictive value of early post‐procedure outcomes [26]. Importantly, the high responder rates observed in the ST and FR groups at 3 months in the present study are consistent with successful surgical outcomes and indicate that substantial clinical improvement had already occurred, even as postoperative healing continues. Finally, objective measures of nasal airflow or anatomic change were not evaluated, limiting the ability to corroborate patient‐reported outcomes with physiologic findings. However, it has been well documented that subjective and objective measures of NAO often do not correlate with one another [38]. Despite these limitations, the findings provide clinically meaningful insight into the comparative effectiveness of TCRF and surgical interventions. TCRF may be considered for patients with symptomatic NVD seeking a minimally invasive option, including those across a range of SD severities. Ultimately, treatment selection should involve shared decision‐making between the physician and patient, considering symptom severity, anatomical findings, and patient preferences. Given that NVD often coexists with SD, TCRF treatment may also serve as a complementary or staged approach alongside ST or FR. Conclusion This prospective trial directly comparing TCRF to ST and FR for the treatment of severe/extreme NAO and NVD demonstrated that TCRF was non‐inferior to both ST and FR for the reduction of NAO symptoms, regardless of SD severity. High responder rates and significant improvements in NOSE scores were observed regardless of treatment type. TCRF was associated with significantly faster RTW and return to normal daily activities compared with both surgical approaches, while maintaining a favorable safety profile. Collectively, these findings demonstrate that TCRF achieves clinically meaningful symptom improvement comparable to surgical intervention, supporting its role as a minimally invasive alternative to surgery in appropriately selected patients. Funding This study was funded by Aerin Medical. Conflicts of Interest Greg Davis: Consultant for Aerin Medical, Medtronic, Regeneron, OptiNose, Spirair, and Neurent Medical. Randall Ow: Consultant for Aerin Medical, Intersect ENT, Lyra Therapeutics, Optinose, Genentech, GlaxoSmithKline, Livanova, and Sanofi. Steven Davis: Consultant for Aerin Medical, Spirair, Inc, Medtronic, and Lyra Therapeutics. Gregory Levitin: Consultant for Neurent Medical. Stacey Silvers: Consultant for Aerin Medical, 3D Matrix, Lyra Therapeutics, and Medical Advisory Board for STStent. Jose Barrera: Consultant for Liva Nova. Zeeshan Aziz: Consultant for Medtronic. William Blythe: Consultant for Inspire Medical Systems. Thomas Higgins: Consultant for Sanofi/Regeneron, Optinose, Genentech, and GlaxoSmithKline. Chris Davis: Consultant for Aerin Medical, Spirair, Sanofi/Regeneron, Genzyme Corporation, and GlaxoSmithKline. The other authors declare no conflicts of interest. Supporting information Supplementary File 1: supinfo/alr70165‐sup‐0001‐SuppMat.docx